Search Results
May 11, 2026, 07:51 ET ProBio and Curocell Achieve Key CAR-T Milestone with BLA Regulatory Approval and Commercial Readiness
Next-generation anti-CD19 CAR-T, Anbal-cel (CRC01), approval highlights Korean innovationHOPEWELL, N.J., May. 11, 2026 /PRNewswire/ -- Given the accelerating global momentum in CAR-T and gene therapies, ProBio Inc. and
More news about: ProBio Inc.
May 11, 2026, 07:00 ET Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape
agonists.LeadsBody (CD3 T-cell Engager) Platform (TCE): Designed to enhance efficacy and overcome treatment resistance, the next-generation LeadsBody platform has been clinically validated in hematologic malignancies by the potential best-in-class (BIC) LBL-034 (GPRC5D/CD3 bispecific antibody).
More news about: Nanjing Leads Biolabs Co., Ltd.
May 11, 2026, 06:15 ET Resideo Announces Filing of Form 10 Registration Statement for Planned Spin-Off of ADI Global Distribution
solutions. He currently serves on the boards of Integrated Power Services and Engineered & Industrial Solutions. Mr. Galvin is an operating advisor of CD&R.Christine Gorjanc is a financial expert who has served as Chief Financial Officer for various companies, including
More news about: Resideo Technologies, Inc.
May 08, 2026, 16:00 ET Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
www.inhibrx.com.About INBRX-106 INBRX-106 is a hexavalent agonist targeting OX40 (CD134), a costimulatory receptor on T-cells. Utilizing Inhibrx's proprietary single-domain antibody (sdAb) platform, INBRX-106 is designed to achieve the
More news about: Inhibrx Biosciences, Inc.
May 07, 2026, 09:01 ET 再鼎醫藥公布 2026年第一季度財務業績和近期公司進展
RAEs發生率為15.2%。– 2026年4月，再鼎醫藥宣布，與安進達成一項全球臨床研究合作，旨在評估zoci聯合安進的IMDELLTRA®（塔拉妥單抗，一款DLL3/CD3雙特異性T細胞銜接器（TCE））用於治療ES-SCLC；與勃林格殷格翰達成一項臨床研究合作，旨在評估zoci聯合obrixtamig（一款DLL3/CD3雙特異性T細胞銜接器）用於治療SCLC及其他NEC。免疫、神經科學和感染性疾病領域管線ZL-1503
More news about: 再鼎醫藥
May 07, 2026, 09:00 ET New Study Recognizes the Powerful Impact of Cranberry Juice to Improve Outcomes for UTIs
Stothart CI, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2023 Nov 10;11(11):CD001321. doi: 10.1002/14651858.CD001321.pub7. PMID: 37947276; PMCID: PMC10636779.
More news about: The Cranberry Institute
May 07, 2026, 08:00 ET Repertoire Immune Medicines Announces FDA Fast Track Designation for its Investigational Immune Medicine, RPTR-1-201
Research and Development at Repertoire Immune Medicines. "Derived from our DECODE™ platform, RPTR-1-201 couples an epitope-specific TCR with an anti-CD3 domain to engage and redirect T cells. Fast Track Designation supports closer dialogue with the FDA as we advance the program and continue its clinical
More news about: Repertoire Immune Medicines
May 07, 2026, 08:00 ET Pierre Fabre Pharmaceuticals Announces Regulatory Update Following Type A Meeting with U.S. Food and Drug Administration (FDA) on Tabelecleucel Biologic License Application (BLA)
(R/R) Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) who have received at least one prior therapy including an anti-CD20 containing regimen.
More news about: Pierre Fabre Pharmaceuticals
May 06, 2026, 22:37 ET ACROBiosystemsとSeromYx Systems、抗CD20モノクローナル抗体の包括的機能プロファイリングに関する戦略的提携を発表
Systemsの生物物理学的・細胞性Fcエフェクター機能プラットフォームを活用し、抗CD20 mAbsの治療上の安全性と有効性を左右する潜在的要因について、新たな画期的知見を引き出します。CD20は、B細胞悪性腫瘍および自己免疫疾患の治療における重要な標的であり、B細胞に選択的に発現するため、長期的な免疫記憶を維持しながら効果的なB細胞除去が可能になります。本研究では、リツキシマブ（RTX）、オファツムマブ（OFA）、オビヌツズマブ（OBZ）の生物物理学的結合および免疫エフェクター機能を比較し、それぞれの作用機序を詳細に解析しました。研究全体を通じて、抗CD20 mAbsの強固な結合プロファイルと、異なるFcエフェクター機能が認められました。
More news about: ACROBiosystems Inc. 株式会社アクロバイオシステムズ
May 06, 2026, 11:34 ET BioOra Limited and Wellington Zhaotai Therapies Limited (WZTL) sign Heads of Terms to Advance their global expansion of CAR T-Cell Therapy
1 Weinkove R, George P, Fyfe R, Hurley A, Dayson N, Nouri Y, et al. A phase 1 dose escalation and expansion trial of third-generation CD19-directed CAR T-cells incorporating CD28 and toll-like receptor 2 (TLR2) co-stimulation for relapsed or refractory B-cell non-Hodgkin lymphomas (ENABLE-1). Blood. 2024;144(Suppl
More news about: BioOra
May 06, 2026, 09:40 ET ATRA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen." Atara said that "[t]he CRL indicates that the FDA is unable to approve the EBVALLO™ BLA in its present form" because, according
More news about: Faruqi & Faruqi, LLP
May 06, 2026, 09:25 ET May 2026 CD Rate Trends: CD Valet Finds More CD Rate Hikes than Cuts for First Time in Months
window to consider strategies like CD laddering, which allows savers to take advantage of today's rates without locking themselves in if the rate environment changes later this year."About CD Valet CD Valet is a CD marketplace that features verified CD rates from federally insured banks
More news about: CD Valet
May 06, 2026, 09:00 ET Collibra Launches AI Command Center to Scale Agentic AI with Real-Time Oversight and Continuous Control
productionized. "Enterprise AI leaders need both top-down governance on how agents are built, and bottom-up tests that operationalize this governance directly inside the CI/CD pipelines of AI engineers," said Alex Combessie, Co-CEO and Co-founder of Giskard. "That's exactly what Giskard and Collibra now deliver together: governance
More news about: Collibra
May 06, 2026, 07:06 ET Kaneka Ubiquinol™ Wins Coveted Vitafoods Europe Innovation Award 2026 in Partnership with Eqology
Marine. Certificate of Analysis: Oxidative Stability Index of Pure Arctic Oil Heart & Energy. Internal method AM29 based on Rancimat method and AOCS Cd 12b-92. October 2025.Kaneka Corporation.
More news about: Kaneka Ubiquinol™
May 06, 2026, 06:34 ET Kaneka Ubiquinol™ Wins Coveted Vitafoods Europe Innovation Award 2026 in Partnership with Eqology
Marine. Certificate of Analysis: Oxidative Stability Index of Pure Arctic Oil Heart & Energy. Internal method AM29 based on Rancimat method and AOCS Cd 12b-92. October 2025.Kaneka Corporation.
More news about: Kaneka Ubiquinol™
May 05, 2026, 16:15 ET Factor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting
synthetic RNA enables selective protein expression in CD8+ T cells (1095)" -to be presented by Joseph Pisano on Tuesday, May 12 from 5:00-6:30 pm, in the "Topic C: Gene Addition: Non-Viral Vectors" Poster Session."TCR-replaced CAR T cells with a mutant CD28 co-stimulatory domain containing TRAF-binding
More news about: Factor Bioscience
May 05, 2026, 10:30 ET El poder de las alianzas: Cómo Beyond ONE conquistó a 7 millones de usuarios globales de la mano de los gigantes de las telecomunicaciones
https://mma.prnewswire.com/media/2967281/5953380/Beyond_One_black_7e0f41fba65117f85a3cd9a65a4a1008_Logo.jpg
More news about: Beyond ONE
May 05, 2026, 09:05 ET RapidScale Delivers AI-Driven Instructional Platform for Trafera, Accelerating Innovation in K-12 Education
teacher inputs—eliminating the need to manually write and maintain thousands of individual lessons.Continuous deployment automation: CI/CD pipelines that allow Trafera to release platform updates quickly without disrupting system stability.Educator-friendly interface: A clean,
More news about: RapidScale
May 05, 2026, 08:05 ET Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) that is refractory to systemic therapies.1,2 The late-breaking presentations from the DUET-UC and DUET-CD studies were among the 32 company-sponsored abstracts being presented at Digestive
More news about: Johnson & Johnson
May 05, 2026, 08:05 ET Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease
inflammation at the cellular source by blocking IL-23 and binding to CD64 (a receptor on cells that produce IL-23). Findings for the dual-acting mechanism are limited to in vitro studies that demonstrate guselkumab binds to CD64, which is expressed on the surface of IL-23 producing cells in an inflammatory
More news about: Johnson & Johnson
May 05, 2026, 08:05 ET AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
for concomitant therapy: A 52-week follow-up of adults with moderately to severely active Crohn's disease treated with risankizumab from the ASPIRE-CD study showed rapid and sustained improvements in abdominal pain, bowel urgency and liquid/soft stools. Among patients with extraintestinal manifestations
More news about: AbbVie
May 05, 2026, 06:45 ET Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
NCT06937086) and COMMIT-CD (
More news about: Eli Lilly and Company
May 04, 2026, 09:00 ET Incredibuild Launches Islo, an Agent Sandbox with Granular Security and Robust Isolation, Bringing Enterprise Controls to AI-Driven Software Development
acceleration capabilities can radically speed up AI-driven software development and reduce the time it takes to execute build, test, and compute-heavy CI/CD steps. This removes potential bottlenecks and allows teams to ship code at the velocity of AI."We've spent years helping teams ship quickly; Islo
More news about: Incredibuild
May 04, 2026, 08:00 ET Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
unexpected benefit of gut microbiome preservation while demonstrating systemic antibacterial activityNeutropenic CD-1 mice were infected intramuscularly with methicillin-resistant Staphylococcus aureus (MRSA) and subsequently treated with one of three Acurx
More news about: Acurx Pharmaceuticals, Inc.
May 04, 2026, 07:30 ET ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl).ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA